Franklin Resources
ADMA icon

Franklin Resources’s ADMA Biologics ADMA Stock Holding History

Franklin Resources’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Sell
203,685
-2,141,214
-91% -$19.5M ﹤0.01% 2068
2026
Q1 		$21.1M Sell
2,344,899
-448,957
-16% -$7.09M 0.01% 966
2025
Q4 		$51M Sell
2,793,856
-44,287
-2% -$746K 0.01% 632
2025
Q3 		$104M Buy
2,838,143
+119,127
+4% +$2.04M 0.03% 430
2025
Q2 		$49.5M Buy
2,719,016
+1,085,286
+66% +$22.1M 0.01% 627
2025
Q1 		$32.4M Buy
1,633,730
+1,306,719
+400% +$22.6M 0.01% 744
2024
Q4 		$5.61M Buy
327,011
+159,367
+95% +$3M ﹤0.01% 1302
2024
Q3 		$2.74M Buy
167,644
+27,180
+19% +$423K ﹤0.01% 1617
2024
Q2 		$1.57M Buy
140,464
+22,575
+19% +$189K ﹤0.01% 1777
2024
Q1 		$778K Buy
117,889
+21,967
+23% +$120K ﹤0.01% 2050
2023
Q4 		$434K Hold
95,922
– – ﹤0.01% 2013
2023
Q3 		$343K Sell
95,922
-4,787
-5% -$18.4K ﹤0.01% 2099
2023
Q2 		$372K Buy
+100,709
New +$373K ﹤0.01% 2117
2021
Q2 		– Sell
-440,201
Closed -$775K – 2013
2021
Q1 		$775K Sell
440,201
-593,591
-57% -$1.36M ﹤0.01% 1530
2020
Q4 		$2.02M Buy
1,033,792
+128
+0% +$269 ﹤0.01% 1292
2020
Q3 		$2.47M Hold
1,033,664
– – ﹤0.01% 1169
2020
Q2 		$3.12M Hold
1,033,664
– – ﹤0.01% 1067
2020
Q1 		$2.98M Buy
+1,033,664
New +$3.57M ﹤0.01% 1021
2017
Q3 		– Sell
-348,870
Closed -$1.34M – 1477
2017
Q2 		$1.34M Sell
348,870
-10,629
-3% -$42.7K ﹤0.01% 1275
2017
Q1 		$1.75M Hold
359,499
– – ﹤0.01% 1266
2016
Q4 		$1.84M Hold
359,499
– – ﹤0.01% 1244
2016
Q3 		$2.61M Hold
359,499
– – ﹤0.01% 1214
2016
Q2 		$2.14M Hold
359,499
– – ﹤0.01% 1243
2016
Q1 		$2.91M Buy
359,499
+104,500
+41% +$597K ﹤0.01% 1198
2015
Q4 		$2.07M Sell
254,999
-9,100
-3% -$81.9K ﹤0.01% 1296
2015
Q3 		$2.21M Sell
264,099
-93,400
-26% -$863K ﹤0.01% 1270
2015
Q2 		$3.31M Hold
357,499
– – ﹤0.01% 1237
2015
Q1 		$3.5M Sell
357,499
-2,638
-0.7% -$26.6K ﹤0.01% 1239
2014
Q4 		$4.02M Buy
+360,137
New +$4.12M ﹤0.01% 1217

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Franklin Resources's ADMA Position: Q2 2026 in Review

Franklin Resources reduced its ADMA Biologics (ADMA) stake by 91% in Q2 2026, selling an estimated $19.5M and leaving 203,685 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2068.

Franklin Resources first reported a position in ADMA in Q4 2014 and has held it in 29 quarters since. The position peaked at $104M in Q3 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Franklin Resources held 203,685 shares of ADMA Biologics worth $1.7M as of Q2 2026.
  • Franklin Resources sold 2,141,214 ADMA Biologics shares in Q2 2026, an estimated $19.5M.
  • ADMA Biologics made up ﹤0.01% of Franklin Resources's portfolio in Q2 2026, its #2068 holding.
  • Franklin Resources first reported a position in ADMA Biologics in Q4 2014 and has held it in 29 quarters since.
  • Franklin Resources's ADMA Biologics position peaked at $104M in Q3 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.